Jun 6, 2026 at 3:52 AM#6
rFC = Recombinant Factor C
Factor C is the specific protein in the horseshoe crab's clotting cascade that initially recognizes and binds endotoxin. Scientists have cloned the gene for Factor C and produced it in insect cells (recombinant DNA technology).
How rFC works:
- Recombinant Factor C is mixed with the sample
- If endotoxin is present, it activates Factor C
- Activated Factor C cleaves a fluorogenic substrate
- The resulting fluorescence is measured — intensity proportional to endotoxin concentration
- No horseshoe crab blood needed
rFC advantages:
1. No animal harvesting required — environmentally sustainable
2. Consistent lot-to-lot performance (recombinant = manufactured uniformly)
3. Less interference from beta-glucans (a common false-positive trigger in LAL)
4. Faster in some implementations
5. Supply chain is more stable and scalable
rFC limitations:
1. Only detects endotoxin via the Factor C pathway. LAL has multiple recognition factors and may detect some non-LPS pyrogenic substances that rFC would miss. (Whether this is a limitation or an advantage depends on perspective — less false positives, but potentially less comprehensive.)
2. Regulatory acceptance: The USP added rFC as a valid alternative method in USP <85> (Bacterial Endotoxins Test) with the 2019 supplement. The FDA has accepted it. But some conservative QA departments still prefer LAL.
3. Currently costs slightly more per test than LAL, though the gap is closing.
Bottom line for you as a patient:
Whether your CoA says "LAL method" or "rFC method," both are valid, USP-accepted methods for endotoxin testing. The fact that your pharmacy IS testing for endotoxins at all and reporting the result on the CoA is the key positive signal. Many less rigorous operations don't test for endotoxins at all.
45 15hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 42 others
Reply Quote Save Share Report